9999999997-17-005944.txt : 20170504
9999999997-17-005944.hdr.sgml : 20170504
20170504140740
ACCESSION NUMBER: 9999999997-17-005944
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20170504
DATE AS OF CHANGE: 20170504
20170504
20170504
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001347178
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030491827
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34186
FILM NUMBER: 17813291
BUSINESS ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
BUSINESS PHONE: 202-734-3400
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR
M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T
M:" V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G +VWPRH@!&(61@X&I#%
MF*&8@:&1@9N!_94]3"77'*B.-K N!DE?")^1#2# .(2!08-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@
M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=
M+TUE9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@." P(%(O4F5S;W5R8V5S
M(#$V(# @4B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH-
M/#PO1FEL=&5R+T9L871E1&5C;V1E+T9II%+;;AHQ$/V5>6P?J"][18J0( EI
MI4)1=M540CPXX,)*>T&[CDK^OC/V+FQHTDA!(Z_M\?;VG&SUJ6!>"C8M=I_U=EV9U GY^Q&.VH@1L7E5%RJWT(.3%*&B;T;EV7I<;G,-G"5&%S_Q/X>N/\HER76V-U7-
M?O5:L8U.5*,IYZWK;\MUM1ZX',HX'Z\A_8BD;+\T
MPC""4 B(HM@.+Q[:+,*'ON_R$*<<5Q4$H66[$[H33W%2P<'',ZB"9HOB6D:Q
MZP7G&'LAK--)>:3!:_'CB:M+[1B^M".//F;'=YWHO^'$6%YFQ(]Z4/)+/'@*
M>A$:_W?AZ^[K7KSO0>N\UD?DKNZU[3WH@+ZK'$?9;G7RWK]A'<=?SM9-K9Z^
M^\C9YWJ[^V6/L[[GG0__"C T#>)O0T*96YD>VUC>\;(9#CVI *G*I24E4&+V$KQ^;\
MTAS_OK-O 1+N3FJ-L'>]N\_,///,^,/-BL)3.[C*!A^R+ *V79 _#QAX_4
MA\0?D1['G@PQ/^LXV\O0P<<+._!W0$'B4T@NS:O,E^-@,O)&EZ7/6([]-4
M'C>#E\<[^89U/78R1UKF'E>A%)G,PEU!EG^NW4O 3WS^SSP(M)DD3GF'YL
M,.5 8JZFD_OE/)N[N)LA (P7UX!&0A([?TP^C1C0)^>7T_QQ/A7R);3<7:+$\,4'HRC
M-\$$EG1I,?LT!4L5DC0UU,!XDL'=#&@:2N8#AQE S *+OATII22-?D#>[WE5
MY/#;+F^>\PWO.[')RQ;FU88HB)CXW[/@R?43MR.@(>8;)[*>0
M)92J_20Y49_SUZ5+[4/=,ZU[29J1%SL*VC\/*K%!60V#ZP5)1)&JD_C<$8F<
MMT&V_5HOB*[C!>253G%*HI%.\1EI5),&^7Y?(D@GZ@KZJN -+'N,/&!K+X"&
M?^EYVXGJR>%,NA>]:C8Z3:_O7.4M6D;(AN\;WB([*G",.'):6!_@//OA
M>?;5-I1 M\L[O(E6(PE&(O4>+%^SP:-8=:
MS=NZ+.L759_:505]J@N^^#H
M$-&R3F8G)%^IPUUIU8$];T1=M-#N^49JJOAH75.XW^R_1IK*'/9)EMK^![9D
MP5650GV"?=P-&%,5W=3]T\XLO9:CG@9T:$=^@!]4F@18G-H=W7:94=I%(_'_
M,')B0YE0G?\8,%YO8SZEV#:%F>%X@E6H2!:M5/!0]@,K=R-IJ_J47A 6U1J]
M)/LA2K9I^[Q2\M5-7J%\]U-;H&Z>6#T4]7E>2
MPL!I\,%&J"7YP"*L-+.=G,NB-$Q_EO,4NP?1
M,E,P4#!7,+10L+'1]RO-+8X&<0T4@F+M[( BP?HN=G8 08 C84(-PT*96YD
MFMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN#IX;7!T:STB061O8F4@6$U0
M($-O"UN&%P+S$N,"\B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @
M(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF
M>41A=&4^,C Q-RTP-2TP-%0Q-#HP-3HT-BTP-#HP,#PO>&UP.DUO9&EF>41A
M=&4^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@
M,3$N," H5VEN9&]W"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M
M(#,T-S$Q+F]R9&5R/"]R9&8Z;&D^"B @(" @(" @(" @(#PO&UP34TZ26YS=&%N8V5)1#YU=6ED
M.F8W,S4T.#,R+3!A8S,M-#8T,BTX8C!A+39C9F$U,3)F,#AD-#PO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#POJ'5!:DZ@?,RQ"H,P%(7A5[F;R:#>V-C2
M(H*851!:ZN)B38J!U)1KI*_?#)V[G>'[SQD0JBIO]K!X8FI?E^G5\KPE,P7K
M5S4%P]2E0''"$J606,ICBC)!3'XJ9OUU)OL.9::=@[NA+9909D56\+SS^O])
M3U[OLR'6S.0?4P!EMV"=,P1"9 @C&^RJ_6<;.<]O-CC#.AOIYI\!!D\:4CC(
M4[1Q&^)U_15@ -EG/T0-"F5N9'-TF4@,3 O5'EP92]84F5F
M+U=;,2 R(#%=/CYS=')E86T-"FC>8F( B9&KMD,3 R,;4""=QZ(U0LBV( 2
MS]8#60P,C$""Z3^08&0 "# >!H%&PT*96YD